HIGH TECH PHARM CO.,LTD.
A pharmaceutical API maker producing carbapenem-class antibiotics Imipenem and Ertapenem, exporting 99.95% of its revenue.
As of 2026-10-08, HIGH TECH PHARM CO.,LTD. has 1 PubMed-indexed paper on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1998 and listed on KOSDAQ in 2010, High Tech Pharm makes sterile injectable antibiotic APIs. Core products are carbapenem antibiotics Imipenem and Ertapenem, and it is developing carbapenem production tech and a next-gen plant. 2025 regional sales were 87.37% Europe, 12.58% Asia, exports 99.95% of revenue; sales KRW 70.18bn, operating profit KRW 12.86bn, net income KRW 11.48bn.
Publications
PubMed · affiliation-matched- Sustainable Approaches for the Protection and Deprotection of Functional Groups.
Chemistry (Weinheim an der Bergstrasse, Germany) · 2025-07 · Jin JH, An M, Jeon M 외 3
Patents
KIPRIS · applicant-matchedRegistered · 2016-05 · Application 1020160065478
Expired · 2009-12 · Application 1020090119263
PCT · Published · 2009-06 · Application PCT/KR2009/003046
Expired · 2008-07 · Application 1020080066378
Registered · 2008-03 · Application 1020080023064
Expired · 2008-03 · Application 1020080022833
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIOAI-SearchBot3
- GoogleGoogleOther3
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
Measured since Aug 27, 2026 · 4 AI engines · last read Sep 28, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for HIGH TECH PHARM CO.,LTD. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition